ArticleNanomedicine : nanotechnology, biology, and medicine2020
Inhibition of choroidal neovascularization by systemic delivery of gold nanoparticles.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- An LSPR-Active AuNP-Silicone Hydrogel Contact Lens for Continuous Ocular Strain Sensing: From Engineering Design to In Vivo Validation.Biosensors · 2026Article
- Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications.Journal of nanobiotechnology · 2025Review
- Toxicity analysis of gold nanoparticle formulations used for intraocular applications.Scientific reports · 2025Article
- Frontier applications of retinal nanomedicine: progress, challenges and perspectives.Journal of nanobiotechnology · 2025Review
- Beyond anti-VEGF: expanding the therapeutic horizon and biomarker landscape in retinopathy of prematurity.Frontiers in pediatrics · 2025Review
- Localization of fluorescent gold nanoparticles throughout the eye after topical administration.Frontiers in medicine · 2025Article
- Nanotechnology in retinal diseases: From disease diagnosis to therapeutic applications.Biophysics reviews · 2024Review
- Article
- Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases.Journal of nanobiotechnology · 2024Review
- Advanced nanomaterials for imaging of eye diseases.ADMET & DMPK · 2024Review
- Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment.Drug delivery · 2023Review
- Roles of biomaterials in modulating the innate immune response in ocular therapy.Frontiers in drug delivery · 2023Review
- Neuronal Bmal1 regulates retinal angiogenesis and neovascularization in mice.Communications biology · 2022Article
- Graphene quantum dots rescue angiogenic retinopathy via blocking STAT3/Periostin/ERK signaling.Journal of nanobiotechnology · 2022Article
- Pharmacological Role of Functionalized Gold Nanoparticles in Disease Applications.Molecules (Basel, Switzerland) · 2022Review
- Nanoparticles in ocular applications and their potential toxicity.Frontiers in molecular biosciences · 2022Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Choroidal neovascularization (CNV) is the abnormal growth of blood vessels that sprout from the choroid vasculature and grow beneath and into the retina. The newly formed blood vessels in CNV often leak blood and fluid which deteriorates vision over time, eventually leading to blindness. In the present study, we examined the efficacy of intravenously injected gold nanoparticles in the laser-induced CNV animal model. Using optical coherence tomography (OCT) and fluorescein angiography, we evaluated CNV lesions longitudinally, over a period of 21 days, with and without nanoparticle treatment. Intravenously injected low concentration of bare gold nanoparticles showed significant anti-angiogenic properties by suppressing CNV development and progression. The treatment group showed significantly decreased fluorescein leakage at the CNV site compared to vehicle injected control mice. OCT assisted CNV volume measurement at all time points showed a significant reduction in lesion size in the treatment group compared with controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.